Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Effects of Curcumin and Its Analogue Desmethoxycurcumin on miR-133b and Its Target Gene GSTP-1 in Cisplatin-resistant Ovarian Cancer Cells

ESİN BAYRALI ÜLKER, ESİN ÇETİN AKTAŞ, MEHMET FATİH SEYHAN, TURGAY İSBİR, DERYANAZ BİLLUR and ÖZLEM TİMİRCİ-KAHRAMAN
Anticancer Research December 2024, 44 (12) 5351-5359; DOI: https://doi.org/10.21873/anticanres.17362
ESİN BAYRALI ÜLKER
1Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkiye;
2Department of Molecular Medicine, Institute of Graduate Studies in Health Sciences, Istanbul University, Istanbul, Turkiye;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ESİN ÇETİN AKTAŞ
3Department of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkiye;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MEHMET FATİH SEYHAN
4Department of Molecular Biology and Genetics, Science Faculty, Istanbul Yeni Yuzyıl University, Istanbul, Turkiye;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TURGAY İSBİR
5Department of Molecular Medicine, Institute of Health Sciences, Yeditepe University, Istanbul, Turkiye
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DERYANAZ BİLLUR
1Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkiye;
2Department of Molecular Medicine, Institute of Graduate Studies in Health Sciences, Istanbul University, Istanbul, Turkiye;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ÖZLEM TİMİRCİ-KAHRAMAN
1Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkiye;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ozlemtk{at}istanbul.edu.tr
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Ovarian cancer, despite being the fifth most common gynecological malignancy, has the highest mortality rate. Recent clinical studies have explored the potential of natural products, like curcumin (CUR), to enhance conventional chemotherapy by targeting multiple cellular pathways. This study aimed to evaluate the effects of CUR and its analog, demethoxycurcumin (DMC), on human ovarian cancer and cisplatin-resistant ovarian cancer cell proliferation and apoptosis. Additionally, we investigated the expression of a candidate gene (GSTP-1), and microRNA (miR-133b) involvement in glutathione metabolism, a potential resistance mechanism in cisplatin-resistant ovarian cancer cells. Materials and Methods: Cell proliferation was measured using the WST-1 assay after exposing cisplatin-resistant (A2780cp) and sensitive (A2780) ovarian cancer cell lines to various concentrations of CUR and DMC for different time periods. Apoptosis was quantified using the Annexin V-FITC/PI assay. To understand the underlying mechanisms, we examined the expression levels of GSTP-1 and miR-133b using quantitative RT-PCR. Results: The WST-1 assay revealed that CUR and DMC inhibited cell proliferation in both cell lines, with cisplatin causing a sharper viability decline in A2780cp cells. Annexin V-PI staining detected early apoptosis induced by CUR, DMC, and their combinations in both cell lines at 12 hours, with no necrosis observed. Gene expression analysis showed a significant decrease in GSTP-1 and miR-133b levels in A2780cp cells compared to A2780 cells. The combination treatments, particularly Cur+DMC+Cisplatin, synergistically reduced GSTP-1 and miR-133b expression. Conclusion: This study demonstrated the potential of CUR and DMC to enhance the efficacy of cisplatin in ovarian cancer treatment. The observed decrease in GSTP-1 and miR-133b expression in cisplatin-resistant cells suggests their involvement in drug resistance and highlights their potential as therapeutic targets.

Key Words:
  • Ovarian cancer
  • curcuminoids
  • resistance
  • gene expression
  • epigenetic
  • Received October 1, 2024.
  • Revision received October 12, 2024.
  • Accepted October 14, 2024.
  • Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
PreviousNext
Back to top

In this issue

Anticancer Research: 44 (12)
Anticancer Research
Vol. 44, Issue 12
December 2024
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Effects of Curcumin and Its Analogue Desmethoxycurcumin on miR-133b and Its Target Gene GSTP-1 in Cisplatin-resistant Ovarian Cancer Cells
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
3 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Effects of Curcumin and Its Analogue Desmethoxycurcumin on miR-133b and Its Target Gene GSTP-1 in Cisplatin-resistant Ovarian Cancer Cells
ESİN BAYRALI ÜLKER, ESİN ÇETİN AKTAŞ, MEHMET FATİH SEYHAN, TURGAY İSBİR, DERYANAZ BİLLUR, ÖZLEM TİMİRCİ-KAHRAMAN
Anticancer Research Dec 2024, 44 (12) 5351-5359; DOI: 10.21873/anticanres.17362

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Effects of Curcumin and Its Analogue Desmethoxycurcumin on miR-133b and Its Target Gene GSTP-1 in Cisplatin-resistant Ovarian Cancer Cells
ESİN BAYRALI ÜLKER, ESİN ÇETİN AKTAŞ, MEHMET FATİH SEYHAN, TURGAY İSBİR, DERYANAZ BİLLUR, ÖZLEM TİMİRCİ-KAHRAMAN
Anticancer Research Dec 2024, 44 (12) 5351-5359; DOI: 10.21873/anticanres.17362
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Methionine Restriction, Not Cysteine Restriction, Is a Cancer-specific Vulnerability
  • Estimation of Tumor Control Probability of Carbon Ion Radiotherapy Using Cancer Type-specific Sensitivity Data
  • Andrographolide Induces Mitochondrial Dysfunction and Alters Stemness-related Gene Expression in MCF7 Breast Cancer Cells
Show more Experimental Studies

Keywords

  • ovarian cancer
  • curcuminoids
  • resistance
  • gene expression
  • epigenetic
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire